Analyst resumed coverage on AtriCure with a new price target
$ATRC
Medical/Dental Instruments
Health Care
Analyst resumed coverage of AtriCure with a rating of Overweight and set a new price target of $40.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/18/2026 | Outperform → Perform | Oppenheimer | |
| 2/11/2026 | $36.00 | Overweight → Neutral | Analyst |
| 12/17/2024 | $40.00 | Overweight | Analyst |
| 4/23/2024 | $32.00 | Perform → Outperform | Oppenheimer |
| 10/23/2023 | $60.00 | Mkt Outperform | JMP Securities |
| 9/29/2023 | $56.00 | Buy | UBS |
| 2/16/2022 | $120.00 → $88.00 | Buy | Canaccord Genuity |
| 2/16/2022 | $92.00 → $79.00 | Buy | Needham |
4 - AtriCure, Inc. (0001323885) (Issuer)
4 - AtriCure, Inc. (0001323885) (Issuer)
4 - AtriCure, Inc. (0001323885) (Issuer)
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 47th Annual Global Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Wednesday, June 10, 2026, at 8:40 a.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company's website at https://ir.atricure.com. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related c
First Quarter 2026 worldwide revenue of $141.2 million, an increase of 14.3% year over year First Quarter 2026 profitability improved, with net income of $0.1 million and adjusted EBITDA of $17.1 million U.S. revenue growth accelerated to 14.9%, driven by AtriClip FLEX-Mini®, cryoSPHERE® MAX™, EnCompass® clamp, and AtriClip PRO-Mini® AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2026 financial results. "Our first quarter results reflect the durability of AtriCure's growth model, fueled by disciplined exe
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Bank of America Securities Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, May 12, 2026, at 10:00 a.m. Pacific Daylight Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company's website at https://ir.atricure.com. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related cond
4 - AtriCure, Inc. (0001323885) (Issuer)
SD - AtriCure, Inc. (0001323885) (Filer)
8-K - AtriCure, Inc. (0001323885) (Filer)
SCHEDULE 13G/A - AtriCure, Inc. (0001323885) (Subject)
Oppenheimer downgraded AtriCure from Outperform to Perform
Analyst downgraded AtriCure from Overweight to Neutral and set a new price target of $36.00
Analyst resumed coverage of AtriCure with a rating of Overweight and set a new price target of $40.00
AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Directors. Mr. Nachman's long and distinguished career in the medical device industry has placed him at the forefront of new market development and growth, serving most recently as Company Group Chairman within Johnson & Johnson's Medical Devices business. Mr. Nachman has over 25 years of experience in the medical device industry and is currently on the board of several private medical device companies, as well as the Arnold and Mable Beck
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief Human Resources Officer, effective today. Ms. Yount will have responsibility for global Human Resources activities. "We are excited to have Deborah joining us at AtriCure," said Michael Carrel, President and Chief Executive Officer. "She brings an incredible amount of industry and human capital expertise as we enter a period of accelerated growth. Our opportunities to address the global Afib epidemic and help patients manage post-operative pain are profo
First Quarter 2026 worldwide revenue of $141.2 million, an increase of 14.3% year over year First Quarter 2026 profitability improved, with net income of $0.1 million and adjusted EBITDA of $17.1 million U.S. revenue growth accelerated to 14.9%, driven by AtriClip FLEX-Mini®, cryoSPHERE® MAX™, EnCompass® clamp, and AtriClip PRO-Mini® AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2026 financial results. "Our first quarter results reflect the durability of AtriCure's growth model, fueled by disciplined exe
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, May 5, 2026, to discuss its first quarter financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https://ir.atricur
Fourth Quarter 2025 worldwide revenue of $140.5 million – an increase of 13.1% year over year Fourth Quarter 2025 net income of $1.8 million and positive adjusted EBITDA of $19.9 million Full Year 2025 worldwide revenue of $534.5 million – an increase of 14.9% year over year Full Year 2025 net loss of $11.4 million and positive adjusted EBITDA of $61.8 million 2025 growth marked by expanding use of new products, including cryoSPHERE® MAX™ and AtriClip FLEX-Mini®, and the continued adoption of EnCompass® clamp AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-o
SC 13G - AtriCure, Inc. (0001323885) (Subject)
SC 13G/A - AtriCure, Inc. (0001323885) (Subject)
SC 13G/A - AtriCure, Inc. (0001323885) (Subject)